神经退行性疾病的热力学
1WaveBreak Therapeutics Ltd., Chemistry of Health, Lensfield Road, Cambridge CB2 1EW, United Kingdom.
Biophysics reviews
|March 25, 2024
概括
大脑中的蛋白质聚合驱动神经退行性疾病,如阿尔茨海默氏症和帕金森症. 这项研究将聚合重新定义为一种与热力学作斗争的系统,以保持健康,无聚合物的状态.
科学领域:
- 神经科学是一个神经科学.
- 生物物理学的生物物理.
- 生物化学 生物化学
背景情况:
- 蛋白质聚合物的形成是神经退行性疾病病理学的核心.
- 对蛋白质自我组装的生物物理洞察力很难应用于复杂的疾病.
- 目前对阿尔茨海默氏症和帕金森病的治疗方法提供有限的治疗方法.
研究的目的:
- 为神经退行性疾病中蛋白质聚合提供一个新的视角.
- 将蛋白质聚合问题重新定义为维持无聚合物状态的系统.
- 通过生物物理见解来探索治疗策略.
主要方法:
- 对蛋白质自我组装的生物物理研究的审查.
- 分析蛋白质聚合中的热力学驱动力.
- 疾病病理学的概念框架开发.
主要成果:
- 蛋白质聚合是一种固有的生物物理过程.
- 热力学力驱使蛋白质向病态聚合.
- 从系统层面的角度来看,强调了保持细胞健康的挑战.
结论:
- 了解蛋白质聚合作为系统层面的挑战对于治疗开发至关重要.
- 未来的疗法应该利用生物物理见解来抵消聚合.
- 观察疾病机制的范式转变可能会加速药物发现.
相关概念视频
Disorders of the Nervous Tissue
1.3K
Nervous tissue is a vital component of the human body's communication system, enabling us to perceive and respond to stimuli. However, like all other tissues, it is vulnerable to disorders and diseases that can significantly impact our neurological functioning.
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
1.3K
Parkinson's Disease: Overview
541
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
541
Alzheimer's Disease: Overview
469
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
469
Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K
Alzheimer's Disease: Treatment
184
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
184
Long-term Potentiation
55.2K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre- and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
55.2K


